114 related articles for article (PubMed ID: 3544404)
1. Antitumoral activity of the oxazaphosphorine derivative, mafosfamide-cyclohexylamine salt (ASTA 7557) on a murine ovarian reticular cell sarcoma and its subline resistant to cyclophosphamide.
Colombo T; Paolini A; Finazzi M; Scanziani E; Mandelli G; Donelli MG
Tumori; 1986 Dec; 72(6):637-42. PubMed ID: 3544404
[TBL] [Abstract][Full Text] [Related]
2. Ovarian reticular cell sarcoma of the mouse (M5076) made resistant to cyclophosphamide.
D'Incalci M; Torti L; Damia G; Erba E; Morasca L; Garattini S
Cancer Res; 1983 Dec; 43(12 Pt 1):5674-80. PubMed ID: 6357429
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of 1,4-bis (2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis Maleate) in M5076 and its subline resistant to cyclophosphamide M5/CTX.
Tagliabue G; Filippeschi S; Hendricks H; D'Incalci M
Ann Oncol; 1992 Mar; 3(3):233-6. PubMed ID: 1586622
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel mouse reticular cell sarcoma M5076 subline resistant to cisplatin.
Ferrari A; Damia G; Erba E; Rossi C; Mandelli R; D'Incalci M
Int J Cancer; 1989 Jun; 43(6):1091-7. PubMed ID: 2659542
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice.
Roberts JD; Hacker MP; Newman RA; McCormack JJ; Krakoff IH
Invest New Drugs; 1984; 2(2):215-20. PubMed ID: 6469517
[TBL] [Abstract][Full Text] [Related]
6. Evidence of a role for NK cells in oxazaphosphorine-mediated tumor regression.
Reissmann T; Hilgard P; Voegeli R; Zeller J
J Cancer Res Clin Oncol; 1989; 115(6):525-30. PubMed ID: 2606928
[TBL] [Abstract][Full Text] [Related]
7. Antineoplastic activity of ASTA Z 7557 (NSC-345842, INN mafosfamide) on transplantable murine tumors.
Atassi G; Hilgard P; Pohl J
Invest New Drugs; 1984; 2(2):169-73. PubMed ID: 6469511
[TBL] [Abstract][Full Text] [Related]
8. Studies on the biology, histology and cytogenetics of two sublines of a murine ovarian reticular cell sarcoma : Biology of M5 and R16 murine tumor.
Donelli MG; Dolfini E; Catapano C; Finazzi M; Mandelli GC; Volontè M; Fuhrman Conti AM
Cytotechnology; 1987 Oct; 1(1):87-90. PubMed ID: 22358448
[TBL] [Abstract][Full Text] [Related]
9. Phase-I study of mafosfamide-cyclohexylamine (ASTA-Z-7557, NSC 345 842) and limited phase-I data on mafosfamide-lysine.
Bruntsch U; Groos G; Hiller TA; Wandt H; Tigges FJ; Gallmeier WM
Invest New Drugs; 1985; 3(3):293-6. PubMed ID: 4066222
[TBL] [Abstract][Full Text] [Related]
10. In vitro cytotoxicity testing of new generation oxazaphosphorines against human histiocytic lymphoma cells.
Opydo-Chanek M; Mazur L; Stojak M
Indian J Exp Biol; 2013 Aug; 51(8):615-22. PubMed ID: 24228385
[TBL] [Abstract][Full Text] [Related]
11. Identification of a methylcholanthrene-induced aldehyde dehydrogenase in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance.
Sreerama L; Sladek NE
Cancer Res; 1994 Apr; 54(8):2176-85. PubMed ID: 8174125
[TBL] [Abstract][Full Text] [Related]
12. Effects of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557).
Kohn FR; Sladek NE
Biochem Pharmacol; 1987 Sep; 36(17):2805-11. PubMed ID: 2820422
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of therapeutic activity, myelotoxicity and DNA damage in the bone marrow of mice after cyclophosphamide and ASTA Z 7557 (INN mafosfamide).
Berger MR; Bedford P; Zeller WJ; Kaufmann M
Invest New Drugs; 1984; 2(2):181-6. PubMed ID: 6469513
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of aldehyde dehydrogenases in murine tumor and hematopoietic progenitor cells to inhibition by chloral hydrate as determined by the ability of chloral hydrate to potentiate the cytotoxic action of mafosfamide.
Maki PA; Sladek NE
Biochem Pharmacol; 1993 Jan; 45(1):231-9. PubMed ID: 8424816
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of cyclohexylamine and lysine salt of mafosfamide.
Abele R; Aapro MS; Haefliger JM; Alberto P
Cancer Chemother Pharmacol; 1986; 16(2):182-3. PubMed ID: 3512115
[TBL] [Abstract][Full Text] [Related]
16. Tumor-associated macrophages stimulate the proliferation of murine tumor cells surviving treatment with the oncolytic cyclophosphamide analogue Asta Z-7557: in vivo implications.
Evans R; Duffy T; Cullen RT
Int J Cancer; 1984 Dec; 34(6):883-90. PubMed ID: 6511127
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide).
Alberts DS; Einspahr JG; Struck R; Bignami G; Young L; Surwit EA; Salmon SE
Invest New Drugs; 1984; 2(2):141-8. PubMed ID: 6469507
[TBL] [Abstract][Full Text] [Related]
18. Schedule-dependent effectiveness of ADM and multiple cycles of DDP on a murine reticulum sarcoma.
Leonetti C; Zupi G; Calabresi F; Greco C
Anticancer Res; 1990; 10(1):45-8. PubMed ID: 2185688
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of toxicity and therapeutic efficacy of a stabilized cytostatic metabolite of cyclophosphamide (ASTA Z 7557, INN mafosfamide).
Klein HO; Wickramanayake PD; Christian E; Coerper C
Invest New Drugs; 1984; 2(2):191-9. PubMed ID: 6469514
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of ASTA Z 7557 (INN mafosfamide) and cyclophosphamide on hematopoiesis in mice.
Nowrousian MR; Schmidt CG
Invest New Drugs; 1984; 2(2):207-13. PubMed ID: 6469516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
